Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Abstract: An electric motor is provided, comprising: a first magnetic component, a second magnetic component, and a circuit configured to electromagnetically activate at least one of the first magnetic component and the second magnetic component. The electromagnetic activation causes a change in a gap between the first magnetic component and the second magnetic component, the change in the gap resulting in rotation of at least one of the first magnetic component and the second magnetic component.

Abstract: Disclosed herein are compositions of tricarbazole triazolophane (tricarb) of Formulas (I), (II) and (III): wherein R of Formula (I) is selected from a group consisting of alkyl (for example, C6-C18), alkyl-substituted phenyl derivatives, and substituted glycol derivatives, among others, or a combination thereof, and R, R? and R? of Formulas (II) and (III) are independently selected from a group consisting of alkyl (for example, C6 to C18), alkyl-substituted phenyl derivatives, and substituted glycol derivatives, or a combination thereof. The disclosure presents examples of thin films composed of the same as well as methods of binding anions from the same.

Abstract: Apparatus and methods for a MEMS-fabricated variable capacitor. In one embodiment the capacitor is a comb drive comprising a plurality of plates interdigitated with a corresponding blades. As the plates move relative to the blades, the capacitance of the sensor changes. The capacitor is sufficiently sensitive to measure respiratory pressure in an animal.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: The present invention provides objective methods of diagnosis and behavioral treatments of neurological disorders such as autism spectral disorders and Parkinson's disease.

Abstract: A genetic biomarker panel is provided for prognosing late onset ER+ breast cancer relapse, in a breast cancer survivor patient. Kits are also provided for measuring levels or the presence of an identified panel of genetic biomarkers. Methods are also provided for identifying a breast cancer survivor patient at a relatively high risk of suffering a breast cancer relapse within 8 years of diagnosis, and therefore suitable for treatment with an aggressive chemotherapeutic regimen. The method may also be used for identifying a breast cancer survivor patient not at high risk of suffering a breast cancer relapse within 8 years of diagnosis, and thus not suitable for treatment with an aggressive chemotherapeutic regimen. The genetic biomarker panel includes an oligonucleotide/nucleic acid sequence specific for the following genes: MKI67, SPAG5, ESPL1, PLK1, or a genetic panel for MKI67, SPAG5, ESPL1, PLK1 and PGR.

Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.

Abstract: A method of determining a predisposition to contact lens discomfort in a patient is provided, comprising determining a detection threshold of the patient by delivering a cool mechanical stimulus to the cornea of the patient, optionally applying a series of cool mechanical stimuli to the cornea of the patient, and classifying the patient as being predisposed to contact lens discomfort if the detection threshold is at or below a cut-off value predetermined to be associated with predisposition to contact lens discomfort and/or the patient does not adapt to the series of cool mechanical stimuli.

Abstract: Methods for imaging a substrate include: inducing an electrospray from a nanopipette probe; varying a distance between the nanopipette probe and a surface of the substrate until a predefined electrospray current and/or a predefined distance threshold is reached; and determining a topography of the surface of the substrate based on feedback derived from distance dependency of the electrospray current. Apparatuses for performing scanning electrospray microscopy and methods for spatially controlled deposition of material on surfaces of substrates are described.

Abstract: Reinforced conductive nanoink formulations are disclosed comprising a carrier, metallic nanostructures dispersed in the carrier, and a reinforcement fiber. Methods of depositing and manufacturing using reinforced nanoinks are also disclosed.

Abstract: The present disclosure provides a method and system including a non-confocal microscope with an attached imaging fiber optic for direct and real time visualization of mammalian microscopic structures for diagnostic and therapeutic uses.

Abstract: Methods for processing an image comprising assigning values to a plurality of pixels of an image, placing the values of the plurality of pixels in an array, determining a method to reference the array values with indices, determining a method to rank or sort the values, sorting the array of values and storing the indices that would sort the array, sorting the array of indices and storing the indices that would sort the array in an array of values, recursively applying these methods, changing methods configurations and/or reusing them during processing, and altering an array based on a sorted array's values and/or indices are disclosed.

Abstract: The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases.

Abstract: A method for synthesizing a graphene-polyaniline hybrid composite, including oxidatively exfoliating natural graphite flakes to yield a graphene body, functionalizing the surface of a graphene substrate with aniline groups wherein the surface of the graphene body is functionalized with aniline groups via a diazonium reaction, and polymerizing the aniline groups, wherein covalently-grafted polyaniline-graphene nanocomposites are formed by in-situ polymerization of aniline in the presence of aniline-functionalized graphene oxide, an oxidant, and an acid dopant.

Abstract: Disclosed herein is that the systemic administration of ASC conditioned media diminished LPS-induced lung injury by inhibiting epithelial permeability, neutrophil inflammatory response, and secretion of pro-inflammatory TNF?. It is also shown that ARDS lung is able to retain IV-delivered ASC for a substantial amount of time, with no evidence of the significant cell distribution to other organs at this time point. These findings provide optimization of cell-based and cell-free therapy for the treatment of ARDS, including occurrences of ARDS caused by upper respiratory tract infections such as SARS and MERS.

Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R1, R2, R3, R4, L1, L2 and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful for labeling penicillin-binding proteins (PBPs).

Abstract: Herein is reported a fusion polypeptide comprising i) one, two, three or four incretin receptor ligand polypeptides, and ii) one human immunoglobulin Fc-region, wherein at least one of the incretin receptor ligand polypeptides comprises an amino acid that is covalently conjugated to a lipid, and wherein each of the one, two, three or four incretin receptor ligand polypeptides is covalently conjugated by a peptide bond to a terminus of the human immunoglobulin Fc-region, whereby to each terminus of the human immunoglobulin Fc-region only a single incretin receptor ligand polypeptide is conjugated.

Abstract: This disclosure is related to the peptide antagonist of LL-37, an antimicrobial peptide that has multiple functions in both innate and adaptive immune response. Specifically, the identified peptide antagonists of LL-37 provide inhibition to detrimental autoimmune inflammatory response, whereas at the same time retain LL-37's antibacterial activity.

Abstract: Methods for the treatment and monitoring of diabetic retinopathy are provided. More specifically, the method for the treatment of diabetic retinopathy comprises administering to an individual suspected of having diabetic retinopathy a composition comprising an agent that inhibits the activity or expression of EMAPII or CXCR3. Methods for diagnosing and monitoring the progression of diabetic retinopathy in an individual, or monitoring the efficacy of a therapy for diabetic retinopathy are provided. More specifically, the method comprises determining the levels of EMAPII in a biological sample from an individual and comparing them to a control or reference sample, or a chronological sample from the individual.